Who are BDP/salbutamol HFA pMDI's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Beclomethasone and Salbutamol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bdp-salbutamol-hfa-pmdi.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

BDP/salbutamol HFA pMDI — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BDP/salbutamol HFA pMDI (BDP/salbutamol HFA pMDI) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination inhaled corticosteroid and short-acting beta-2 agonist (ICS/SABA). Area: Respiratory / Pulmonology.

phase 3 Combination inhaled corticosteroid and short-acting beta-2 agonist (ICS/SABA) Glucocorticoid receptor (BDP); Beta-2 adrenergic receptor (salbutamol) Respiratory / Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

BDP/salbutamol HFA pMDI (BDP/salbutamol HFA pMDI) — Chiesi Farmaceutici S.p.A.. BDP/salbutamol is a combination inhaler that reduces airway inflammation via corticosteroid action while providing rapid bronchodilation through beta-2 agonist stimulation.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
BDP/salbutamol HFA pMDI TARGET	BDP/salbutamol HFA pMDI	Chiesi Farmaceutici S.p.A.	phase 3	Combination inhaled corticosteroid and short-acting beta-2 agonist (ICS/SABA)	Glucocorticoid receptor (BDP); Beta-2 adrenergic receptor (salbutamol)
Beclomethasone and Salbutamol	Beclomethasone and Salbutamol	University of Calgary	marketed	Combination inhaled corticosteroid and short-acting beta-2 agonist (ICS/SABA)	Glucocorticoid receptor (beclomethasone); beta-2 adrenergic receptor (salbutamol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination inhaled corticosteroid and short-acting beta-2 agonist (ICS/SABA) class)

Chiesi Farmaceutici S.p.A. · 1 drug in this class
University of Calgary · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BDP/salbutamol HFA pMDI — Competitive Intelligence Brief. https://druglandscape.com/ci/bdp-salbutamol-hfa-pmdi. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab